Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Manitoba

$25,000.00

Characterization of PEGylated DispersinB

EF 2011-12

Résumé
Kane Biotech a Canadian Biotechnology Company is developing commercial products for wound care and medical devices that result in the prevention and removal or dispersion of bacterial biofilms. Biofilms develop on surfaces such as wounds, catheters, prosthetic implants, teeth, lungs and the urogenital tract and are a major cause of a number of serious medical problems. For instance, biofilms are the major cause of wound care product failures because antibiotic treatments are not effective against bacteria in a biofilm. In addition, biofilms are also a major cause of hospital acquired catheter-associated infections as 80% of all hospital acquired infections are device related with 50% deriving from urinary and venous catheters. Kane's core technology focuses on the application of DispersinB an antibiofilm enzyme, which inhibits and disperses biofilms of bacterial pathogens. However, recent studies indicate that DispersinB suffers several drawbacks including reduced thermo- and proteolytic stability, low solubility and immunoreactivity. In order to overcome these drawbacks it is hypothesized that polyethyleneglycol (PEG)-modified DispersinB will exhibit superior biological and physicochemical properties when compared to native DispersinB. Covalent attachment of PEG groups a process commonly called PEGylation is often used to improve the performance of proteins. To date, at least eight such PEGylated peptide and protein conjugates have been approved as therapeutic agents. This study will integrate the research strength of Dr. Frank Schweizer's lab in synthetic conjugation chemistry. In the six months of granting period under this NSERC Engage grant, the team will prepare various PEGylated DispersinB analogs differing in PEGylation method, average molecular weight and shape and will study their enzymatic-, antibiofilm forming-, immunoreactive-properties as well as their solubility and thermostability. The goal is to develop DispersinB analogs with superior biomedical properties when compared to non-PEGylated Dispersin B that will be developed into novel commercial products. The outcomes of the proposed study will contribute to savings in health care costs and to generate revenues.
Programme
Engage Grants Program
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
416525-2011
Name nom
Schweizer, Frank
Department département
Chemistry
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Characterization of PEGylated DispersinB
Keyword
NSERC
Application summary
Kane Biotech a Canadian Biotechnology Company is developing commercial products for wound care and medical devices that result in the prevention and removal or dispersion of bacterial biofilms. Biofilms develop on surfaces such as wounds, catheters, prosthetic implants, teeth, lungs and the urogenital tract and are a major cause of a number of serious medical problems. For instance, biofilms are the major cause of wound care product failures because antibiotic treatments are not effective against bacteria in a biofilm. In addition, biofilms are also a major cause of hospital acquired catheter-associated infections as 80% of all hospital acquired infections are device related with 50% deriving from urinary and venous catheters. Kane's core technology focuses on the application of DispersinB an antibiofilm enzyme, which inhibits and disperses biofilms of bacterial pathogens. However, recent studies indicate that DispersinB suffers several drawbacks including reduced thermo- and proteolytic stability, low solubility and immunoreactivity. In order to overcome these drawbacks it is hypothesized that polyethyleneglycol (PEG)-modified DispersinB will exhibit superior biological and physicochemical properties when compared to native DispersinB. Covalent attachment of PEG groups a process commonly called PEGylation is often used to improve the performance of proteins. To date, at least eight such PEGylated peptide and protein conjugates have been approved as therapeutic agents. This study will integrate the research strength of Dr. Frank Schweizer's lab in synthetic conjugation chemistry. In the six months of granting period under this NSERC Engage grant, the team will prepare various PEGylated DispersinB analogs differing in PEGylation method, average molecular weight and shape and will study their enzymatic-, antibiofilm forming-, immunoreactive-properties as well as their solubility and thermostability. The goal is to develop DispersinB analogs with superior biomedical properties when compared to non-PEGylated Dispersin B that will be developed into novel commercial products. The outcomes of the proposed study will contribute to savings in health care costs and to generate revenues.